Kornimate/medical-research-clean huggingface dataset:
treatment of functional dyspepsia with genuine regional rhizoma atractylodis

Conditions: Efficiency of Genuine Regional and Non-genuine Regional Rhizoma Atractylodis in Treating FD

Summary: this is a randomized double-blind placebo controlled trial aim to compare the efficiency of genuine regional and non-genuine regional rhizoma atractylodis in treating functional dyspepsia. this study will also observe the clinical safety of genuine regional rhizoma atractylodis.the trial will be conducted in xiyuan hospital of china academy of chinese medicine sciences and dongzhimen hospital of beijing university of chinese medicine.


Eligibility criteria:
inclusion criteria: 1. meeting the fd rome ⅲ diagnosis standard; 2. meeting tcm differentiated diagnosis standard of the spleen deficiency with dampness pattern; 3. without taking any medicines affecting gastric motility in the recent 14 days; 4. between 18 and 65 years old; 5. voluntary participation in the trial and signing informed consent. exclusion criteria: 1. combined irritable bowel syndromes; combined peptic ulcer, erosive gastritis, atrophic gastritis, abdominal surgery history, gastric mucosa with severe dysplasia or pathological diagnosis of suspected malignant transformation; combined gastroesophageal reflux disease, irritable bowel syndrome with overlapping syndromes. 2. patient whose differentiation is not clear or who doesn't belong to the spleen deficiency with dampness pattern. 3. women in pregnancy, breastfeeding or have fertility plans recently; the legally disabled (blind, deaf, dumb, mental retardation, mental disorders, physical disability) 4. patients with endocrine and metabolic diseases such as connective tissue diseases, diabetes, menopausal syndromes; patients combined with heart rate disorder, severe diseases in cardiovascular, brain, liver, lung, kidney and hematopoietic systems, acute and chronic infectious diseases, malignant tumors, mental illness. 5. allergy to the trial drug. 6. with suspected or definite alcohol, drug abuse history.
clown care for botulinum toxin (btx)

Conditions: Cerebral Palsy; Pain

Summary: children with cerebral palsy (cp) undergo multiple painful procedures such as botulinum toxin (btx) injections that are administered several times a year. while clown care reduces preoperative anxiety, its effect on painful procedures has not been assessed. we hypothesized that medical clowning reduces pain and anxiety during btx injections.

patients and methods: twenty five children with cp (mean age 7.4±4.8 years; 19 boys), enrolled in this randomized controlled study underwent btx injections (3±1.7 muscles per procedure). prior to treatment each child was assigned to receive either medical clown intervention (study) or standard care (control). outcome measure was the visual analogue scale (vas) as reported by the child (n =14) or parent (n =11) prior and subsequent to each procedure.

Eligibility criteria:
inclusion criteria: * children with cp for whom btx treatment was indicated exclusion criteria: * children with minimal communication skills (n =1) * autistic spectrum disorders (n =1) * severe anxiety requiring general anesthesia (n =1)

Keywords: needle, anxiety, pain, clowns
meta-analysis of stannous fluoride and the effects on dental plaque

Conditions: Dental Plaque

Summary: the aim of this 18 study analysis was to compare the effect of bioavailable stannous fluoride (snf2) dentifrices when used up to 3 months on dental plaque relative to a positive or negative control dentifrice.


Eligibility criteria:
subjects were excluded from this study for the following reasons; * pregnancy, * rampant caries, * severe periodontitis, * at discretionary of the principal investigator.
laser cell therapy for knee cartilage repair

Conditions: Knee Osteoarthritis

Summary: laser pulsed energy will be delivered over an optical fiber to create channels into damaged cartilage of the knee or knees. the channels have a diameter of approximately 100 microns or less and an approximate depth of 1 millimeter or less. bone marrow aspirate will then be delivered into the damaged joint.

the creation of micro-channels into damaged knee cartilage will facilitate the movement of fluid into and out of the tissue to allow for more efficient nutrient diffusion. the addition of bone marrow aspirate will provide additional growth factor enriched nutrition to the tissue. the goal of this combination therapy is to facilitates the body's own reparative processes leading to improved patient well being.

Eligibility criteria:
inclusion criteria: kellergren grading scale of 2 or 3 in at least one compartment of either or both knees with no compartment representing a stage 4 in either knee. no significant mcl or lcl tear or laxity no significant meniscal tear. ( i.e. bucket handle) exclusion criteria: * injection with the past 6 weeks * stage 4 osteoarthritis in either knee * uncontrolled diabetes or any other metabolic syndrome * bmi greater than 28 * significant lower extremity deformity * bilateral or tri compartmental knee oa * adults unable to consent * individuals who are not yet adults (infants, children, and teenagers, age \< 18) * pregnant women * prisoners * stage 4 osteoarthritis in either knee * subjects, who, in the opinion of the investigator, for any reason other than those listed above, will not be able to complete the study per protocol.
frailty: prevalence and response to left ventricular assist device therapy in older heart failure patients

Conditions: Systolic Heart Failure

Summary: this is an observational study evaluating changes in frailty and associated impairments in older heart failure patients receiving left ventricular assist device therapy.


Eligibility criteria:
inclusion criteria: * 60 years old or older * scheduled to undergo left ventricular assist device implantation at thomas jefferson university exclusion criteria: * unable or unwilling to provide informed consent * unable to complete baseline frailty assessment

Keywords: ventricular assist device skeletal muscle frailty older adults
wound-healing improvement by resurfacing split-thickness skin donor sites with thin split-thickness grafting

Conditions: Skin Graft Disorder; Disorder of Skin Donor Site; Wound Healing Disturbance of

Summary: split-thickness skin grafting remains fundamental treatment of patients with deep burns and other traumatic injuries. however, the split-thickness skin graft (stsg) donor site dressing has been controversial until now. our study here aimed to assess patient comfort and wound-healing efficacy with the application of thin split-thickness grafting on stsg donor sites.

background：split-thickness skin grafting remains fundamental treatment of patients with deep burns and other traumatic injuries. however, the split-thickness skin graft (stsg) donor site dressing has been controversial until now. our study here aimed to assess patient comfort and wound-healing efficacy with the application of thin split-thickness grafting on stsg donor sites. methods: 192 consecutive patients undergoing split-thickness skin grafting were included in the study and the participants were randomly divided into three groups: group a was regrafted with thin stsg, while, group b and group c were covered with the occlusive hydrocellular dressing and paraffin gauze, respectively. the three groups were compared regarding to the time of epithelialization, pain sensed by the patients and the scar formation.

Eligibility criteria:
inclusion criteria: * patients who continuously received an stsg from january 2002 to december 2010 in department of burn and plastic surgery, tangdu hospital, fourth military medical university exclusion criteria: * the patients who were significant psychiatric, hypersensitive to silver, and not be followed up were excluded

Keywords: the split-thickness skin graft （stsg） donor site regraft wound healing
assessment of the accuracy of the non-invasive wireless armband gabi baby band for continuous vital parameters monitoring in infants and young children

Conditions: Blood Oxygen Desaturations; Sleep-Disordered Breathing

Summary: during a polysomnography test (psg) previously prescribed by a physician, the patient also wears the gaby baby band (gbb) during an entire night of sleep. after the test, data from the device and from the psg (hr, spo2, br) will be saved and analysed in the aim to assess the actual accuracy of the gbb with golden standard values (ecg, oximeter, belly belt). in a second analysis, the aim is to improve the accuracy of the gbb algorithm.


Eligibility criteria:
inclusion criteria: * infants and children under 5 years of age * psg is required per standard of care * signature of consent form exclusion criteria: * children having already done the psg wearing gbb for this study * epileptic children (due to high motion/artifacts during sleep) * weight below 2.5 kg
computerized cognitive behavioral therapies for suicide prevention and depression

Conditions: Suicide; Depression

Summary: this study plans to learn more about the use of one of two self-guided online cognitive behavioral therapy courses. one is focused on symptoms of depression and one is focused on history of suicidal thoughts and behaviors.

based on previous work with other computerized cbt (ccbt) interventions (e.g., ccbt-d), which has found that ccbt has similar effectiveness to traditional cbt, members of the team along with veterans health administration (vha) leaders have developed computerized ccbt-sp and ccbt-d courses that will be ready for safety, feasibility, and acceptability testing. if proven to be feasible, safe, and effective, these courses could be made available to all veterans, at no cost to users.

Eligibility criteria:
cohort a - ccbt-sp program inclusion criteria: 1. veterans between the ages of 18 and 65 2. currently living in colorado, new york, montana, texas, or utah who have accessed va care 3. recent suicidal ideation (past month; c-ssrs screener -yes to item 2) and history of lifetime suicidal behavior (lifetime, c-ssrs screener - yes to item 6) 4. reliable access to a computer/tablet and the internet 5. ability to provide informed consent exclusion criteria: 1. active alcohol or substance use disorder, excluding cannabis dependence, as determined by screening or electronic medical record 2. identification of active psychosis or bipolar disorder, as determined via screening or electronic medical record 3. severe cognitive impairment, as determined by screening or electronic medical record 4. currently enrolled in/participating in another mental health-related intervention research study cohort b - ccbt-d program inclusion criteria: 1. veterans between the ages of 18 and 65 2. currently living in colorado, new york, montana, texas, or utah who have accessed va care 3. mild to moderate depressive symptoms, as determined by the phq-9, (score of 5-14) 4. reliable access to a computer/tablet and the internet 5. ability to provide informed consent exclusion criteria: 1. phq-9 score below 4 or 15 and above 2. active alcohol or substance use disorder, excluding cannabis dependence, as determined by screening or electronic medical record 3. identification of active psychosis or bipolar disorder, as determined via screening or electronic medical record 4. severe cognitive impairment, as determined by screening or electronic medical record 5. currently enrolled in/participating in other intervention research study

Keywords: suicide depression veterans cognitive behavioral therapy
interest of lidocaine in children with upper airway infection undergoing general anesthesia

Conditions: Upper Respiratory Tract Infections; Perioperative Respiratory Complications

Summary: the goal of this clinical trial is to determine whether intravenous (iv) lidocaine reduces the incidence of perioperative respiratory complications (prcs) in children with upper respiratory tract infections undergoing general anesthesia. the study will also evaluate the safety of iv lidocaine in this population. the main questions it aims to answer are: 1. does iv lidocaine lower the incidence of perioperative respiratory complications (e.g., laryngospasm, cough, desaturation) compared to a placebo? 2. what are the side effects associated with the administration of iv lidocaine in these children? researchers will compare iv lidocaine to a placebo to assess its effectiveness in reducing prcs.


Eligibility criteria:
inclusion criteria: * children aged 1 to 14 years. * american society of anesthesiologists (asa) physical status classification i, ii, or iii. * scheduled or urgent surgery or radiological exploration under general anesthesia. * upper respiratory tract infection (urti) symptoms present for less than 15 days. exclusion criteria: * refusal of participation by parents. * children on long-term corticosteroid or bronchodilator therapy. * contraindications to the use of lidocaine or other drugs used in the protocol. * patients who did not adhere to the study protocol.

Keywords: upper respiratory tract infections iv lidocaine general anesthesia children laryngospasm bronchospasm cough perioperative respiratory complications
cranberry tablets versus nitrofurantoin prophylaxis for urinary tract infection prevention after urogynecologic surgery

Conditions: Urinary Tract Infections; Pelvic Organ Prolapse; Urinary Incontinence

Summary: we aim to compare the effectiveness of cranberry capsules versus nitrofurantoin prophylaxis in preventing urinary tract infections (utis) after urogynecologic surgery by conducting a double-blinded randomized clinical trial involving women with pelvic organ prolapse and/or urinary incontinence scheduled to have surgery with the urogynecologists who comprise the brigham and women's urogynecology group.

we plan to conduct a double-blinded randomized clinical trial involving women who undergo surgery for pelvic organ prolapse and/or urinary incontinence. participants who need transurethral catheterization postoperatively will be randomized to cranberry capsules or nitrofurantoin prophylaxis. randomization will be performed the day of discharge. both participants and surgeons will be blinded to treatment allocation. all participants will receive routine perioperative intravenous antibiotic prophylaxis. participants who fail their voiding trial after surgery and require transurethral catheterization upon discharge from the hospital will be randomized to either one cranberry capsule (theracran one®, theralogix, llc, rockville, maryland) or one 100 mg capsule of nitrofurantoin by mouth daily beginning postoperative day #1. participants randomized to the cranberry capsule group will continue to take one cranberry capsule daily for 28 days. participants randomized to the nitrofurantoin group will continue to take 100 mg of nitrofurantoin each day transurethral catheterization is needed for up to 28 days. all participants will be scheduled for a repeat voiding trial within 48 hours to 1 week after discharge. all participants will complete a daily catheterization and medication diary to record the type of catheterization used (indwelling or intermittent) and to confirm they are taking the study medication for the duration of the study period. they will also be asked to record any urinary symptoms they experience and will be encouraged to contact the office immediately if they experience urinary symptoms consistent with a uti.

Eligibility criteria:
inclusion criteria: * age ≥ 18 * english-speaking * plan for pelvic organ prolapse (pop) or urinary incontinence (ui) surgery exclusion criteria: * pregnancy * urethral diverticulectomy * urogenital fistula repair * sacral neuromodulation * congenital urogenital anomaly * allergy to cranberry products * allergy to nitrofurantoin * dependent on catheterization preoperatively * recurrent uti's (3 or more culture proven uti's over the past consecutive 12 months) * known creatinine clearance \<60 ml/min * non-english, non-spanish speaking
anti ct-p13 antibody in moderate to severe inflammatory bowel disease

Conditions: Inflammatory Bowel Disease; Ulcerative Colitis; Crohn's Disease

Summary: the purpose of this study is to evaluate the development of anti-drug antibody to biosimilar ct-p13 and to assess the change of drug concentration for 1 year in patients with moderately to severe inflammatory bowel disease.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of crohn's disease or ulcerative colitis exclusion criteria: * tuberculosis infection * allergy to ct-p13

Keywords: inflammatory bowel disease biosimilar anti-drug antibody trough drug concentration
caduet in an untreated subject population

Conditions: Hypertension; Dyslipidemia

Summary: the purpose of this study is to determine if caduet will lower blood pressure to \<140/90 mmhg and lower ldl cholesterol to \<100 mg/dl in subjects with hypertension and dyslipidemia who are not currently being treated for these medical conditions.


Eligibility criteria:
inclusion criteria: * subjects who were recently diagnosed with both hypertension and dyslipidemia and who are not yet taking any medications for these conditions or subjects with both hypertension and dyslipidemia who were previously treated with antihypertensive and/or lipid lowering medications but discontinued these medications for at least 3 months prior to the screening visit. * sbp 140-169 mmhg and/or dbp 90-105 mmhg, ldl-c 110-160 mg/dl exclusion criteria: * subjects with a history of mi, angina, coronary artery bypass or intra-coronary interventions, stroke, tia, chf or cardiomyopathy requiring treatment. * subjects with a known history of type i or type 2 diabetes mellitus or a fasting blood glucose \> 126 mg/dl at the screening visit.
an investigational immuno-therapy study of nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread

Conditions: Colorectal Cancer; Colorectal Tumors; Colorectal Carcinoma; Colorectal Neoplasm

Summary: the purpose of this study is to investigate treatment with nivolumab in combination with trametinib with or without ipilimumab in participants with previously treated cancer of the colon or rectum that has spread.


Eligibility criteria:
inclusion criteria: * histologically or cytologically confirmed previously treated metastatic colorectal cancer with adenocarcinoma histology and in stage iv per american joint committee on cancer (version 4.0) at study entry * microsatellite status should be performed per local standard of practice, immunohistochemistry (ihc) and/or pcr. if ihc results are equivocal, pcr is required for determining microsatellite stable (mss) status * must have measurable disease per recist 1.1. participants with lesions in a previously irradiated field as the sole site of measurable disease will be permitted to enroll provided the lesion(s) have demonstrated clear progression and can be measured accurately * eastern cooperative oncology group (ecog) performance status of 0-1 at screening and on cycle 1 day 1 (c1d1) exclusion criteria: * braf v600 mutant colorectal cancer * active brain metastases or leptomeningeal metastases * active, known or suspected autoimmune disease * participants with a condition requiring systemic treatment with either corticosteroids (\> 10 mg daily prednisone equivalents) or other immunosuppressive medications within 14 days of study treatment administration * history of interstitial lung disease or pneumonitis * prior treatment with immune checkpoint inhibitors and mitogen-activated protein kinase enzymes (mek) inhibitors * history of allergy or hypersensitivity to study drug components other protocol defined inclusion/exclusion criteria apply
detection of circulating endothelial progenitors cells (epcs) in non-small cell lung cancer (nsclc)

Conditions: Non-Small Cell Lung Cancer; Chronic Obstructive Pulmonary Disease

Summary: bone-marrow-derived progenitor cells (epcs) play an important role in neovascularization and tumor growth. in lung cancer, angiogenesis is an important event in mechanisms of tumor proliferation and metastasis. recent evidences suggest that epcs can be recruited and differentiate in mature endothelial cells to form new blood vessels. the role of epcs in nsclc is unclear. in contrast, angiogenic drugs are proposed combined to systemic chemotherapy in nsclc. the aim of this study is to identify epcs in peripheral blood from patients with nsclc, by comparison to chronic pulmonary obstructive disease (copd), an inflammatory disease.

the aim of this study is to study blood circulating levels bone-marrow-derived progenitor cells (epcs). in a first phase, epcs will be detected in healthy non-smokers volunteers to validate flow cytometry method (n=25). in addition, epc will e characterized by primary cultures to analyze epc-specific markers. in a second phase, epcs will detect in peripheral blood from 50 patients with chronic obstructive pulmonary disease (copd) and 50 patients with non-small cell lung cancers (nsclc). primary cultures will be made to confirm epcs isolation. methods: epcs will be numerated by flow cytometry using cd133, cd146, cd34, cd45 and vegfr2 antibodies. primary cultures will be used to identify epcs at 5-days culture by the same markers. in addition, for bpco et nsclc patients, vascular endothelial cell growth factor (vegf) concentration will be measured in peripheral sera by elisa commercial test. overall survival will be analyzed for nsclc in function of initial epcs concentration. correlation will be studied between initial vegf serum concentration and epcs level. this study focus on the possibility that epc determination in peripheral blood could be used as a surrogate marker of standard or antiangiogenic treatment in nsclc.

Eligibility criteria:
inclusion criteria: * signed written consent * subject \> 18 year old * no precedent therapy for cancer * non-smoker healthy subject or current smoker copd patients or nsclc patients exclusion criteria: * small-cell lung cancer patient * radiotherapy, chemotherapy or target therapy for nsclc

Keywords: non-small cell lung cancer endothelial cell progenitor angiogenesis vascular endothelial cell growth factor healthy control copd patients nsclc patients
special drug use investigation for arixtra (fondaparinux) abdominal (urology,obstetrics,gynecology)

Conditions: Cardiovascular Disease

Summary: the purpose of this study is to collect and assess information on safety and efficacy of fondaparinux in patients undergoing abdominal surgery in urology, obstetrics and gynecology departments who are at high risk of venous thromboembolism.


Eligibility criteria:
inclusion criteria: * patients undergoing abdominal surgery in urology, obstetrics and gynecology departments exclusion criteria: * patients with a history of hypersensitivity to the ingredients of fondaparinux * patients with bleeding (bleeding in important organs, sucn as retroperitoneal bleed) * patients with acute bacterial endocarditis * patients with severe renal impairment
binaural sound for remimazolam maintenance

Conditions: General Anesthesia; Prostate Cancer Stage; Uterine Myoma

Summary: it is important to decrease the remifentanil dose for general anesthesia maintenance when using remimazolam. we will evaluate the effect of binaural sound on general anesthesia maintenance with remimazolam infusion.


Eligibility criteria:
inclusion criteria: 1. patients scheduled for general anesthesia 2. patients aged 20-60 3. patients with american society of anesthesiologist physical status classification 1-2 4. patients with ideal body weight 50-80 kg exclusion criteria: 1. patients with hearing disability 2. patients using opioids or sedatives in 1 week 3. patients who are dependent for alcoholics or drugs 4. patients with hypersensitivities to remimazolam or remifentanil 5. patients with arrhythmia, cardiovascular disease, heart failure, or hypovolemia 6. patients with liver failure